These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 2889454)
21. [3H]yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Hamilton CA; Reid JL; Yakubu MA Eur J Pharmacol; 1988 Feb; 146(2-3):345-8. PubMed ID: 3371405 [TBL] [Abstract][Full Text] [Related]
22. Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines. Erdbrügger W; Raulf M; Otto T; Michel MC J Pharmacol Exp Ther; 1995 Jun; 273(3):1287-94. PubMed ID: 7791100 [TBL] [Abstract][Full Text] [Related]
23. [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase. Renouard A; Widdowson PS; Cordi A Br J Pharmacol; 1993 Jul; 109(3):625-31. PubMed ID: 8102932 [TBL] [Abstract][Full Text] [Related]
24. [3H]-idazoxan binds with high affinity to two sites on hamster adipocytes: an alpha 2-adrenoceptor and a non-adrenoceptor site. MacKinnon AC; Brown CM; Spedding M; Kilpatrick AT Br J Pharmacol; 1989 Dec; 98(4):1143-50. PubMed ID: 2558757 [TBL] [Abstract][Full Text] [Related]
25. Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. Boyajian CL; Loughlin SE; Leslie FM J Pharmacol Exp Ther; 1987 Jun; 241(3):1079-91. PubMed ID: 3037066 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain. Boyajian CL; Leslie FM J Pharmacol Exp Ther; 1987 Jun; 241(3):1092-8. PubMed ID: 2885406 [TBL] [Abstract][Full Text] [Related]
27. Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan. Reader TA; Brière R; Grondin L J Neural Transm; 1987; 68(1-2):79-95. PubMed ID: 2879884 [TBL] [Abstract][Full Text] [Related]
28. [3H]RX821002: a new tool for the identification of alpha 2A-adrenoceptors. Langin D; Lafontan M; Stillings MR; Paris H Eur J Pharmacol; 1989 Aug; 167(1):95-104. PubMed ID: 2570706 [TBL] [Abstract][Full Text] [Related]
29. Discrimination between alpha 2-adrenoceptors and [3H]idazoxan-labelled non-adrenergic sites in rabbit white fat cells. Langin D; Paris H; Dauzats M; Lafontan M Eur J Pharmacol; 1990 Apr; 188(4-5):261-72. PubMed ID: 1973120 [TBL] [Abstract][Full Text] [Related]
30. [3H]idazoxan binding to bovine adrenal medullary membranes: identification and pharmacological characterization of I2-imidazoline sites. Molderings GJ; Kundt L; Göthert M Naunyn Schmiedebergs Arch Pharmacol; 1994 Sep; 350(3):252-7. PubMed ID: 7824041 [TBL] [Abstract][Full Text] [Related]
31. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. Miralles A; Olmos G; Sastre M; Barturen F; Martin I; Garcia-Sevilla JA J Pharmacol Exp Ther; 1993 Mar; 264(3):1187-97. PubMed ID: 8095548 [TBL] [Abstract][Full Text] [Related]
32. Imidazolinic radioligands for the identification of hamster adipocyte alpha 2-adrenoceptors. Saulnier-Blache JS; Carpéné C; Langin D; Lafontan M Eur J Pharmacol; 1989 Nov; 171(2-3):145-57. PubMed ID: 2575998 [TBL] [Abstract][Full Text] [Related]
33. Characterization of an imidazoline/guanidinium receptive site distinct from the alpha 2-adrenergic receptor. Parini A; Coupry I; Graham RM; Uzielli I; Atlas D; Lanier SM J Biol Chem; 1989 Jul; 264(20):11874-8. PubMed ID: 2545687 [TBL] [Abstract][Full Text] [Related]
34. Structure-affinity relationship of cirazoline derivatives for idazoxan imidazoline-specific sites in the human cerebral cortex and the rabbit kidney. Brasili L; Pigini M; Ehrhardt JD; Molines A; Greney H; Bousquet P; Dontenwill M Ann N Y Acad Sci; 1995 Jul; 763():149-52. PubMed ID: 7677323 [No Abstract] [Full Text] [Related]
35. Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells. Gargalidis-Moudanos C; Parini A J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S59-62. PubMed ID: 8642808 [TBL] [Abstract][Full Text] [Related]
37. New tools for human fat cell alpha-2A adrenoceptor characterization. Identification on membranes and on intact cells using the new antagonist [3H]RX821002. Galitzky J; Larrouy D; Berlan M; Lafontan M J Pharmacol Exp Ther; 1990 Jan; 252(1):312-9. PubMed ID: 1967647 [TBL] [Abstract][Full Text] [Related]
38. Characterization of imidazoline-guanidinium receptive sites in renal medulla from human kidney. Lachaud V; Limon I; Tesson F; Coupry I; Parini A Am J Hypertens; 1992 Apr; 5(4 Pt 2):69S-71S. PubMed ID: 1350730 [TBL] [Abstract][Full Text] [Related]
39. Evidence that drug binding to non-adrenergic [3H]-idazoxan binding sites (I-receptors) occurs to interacting or interconvertible affinity forms of the receptor. Wikberg JE; Uhlén S; Chhajlani V Pharmacol Toxicol; 1992 Mar; 70(3):208-19. PubMed ID: 1349748 [TBL] [Abstract][Full Text] [Related]
40. [Interaction of rilmenidine with renal imidazoline-guanidine sites]. Lachaud V; Bidet M; Coupry I; Podevin RA; Poujeol P; Parini A Arch Mal Coeur Vaiss; 1989 Dec; 82 Spec No 5():15-8. PubMed ID: 2576516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]